Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Overview | Financials
Company Name | Iovance Biotherapeutics, Inc. |
Symbol | IOVA |
Currency | USD |
Price | 5.89 |
Market Cap | 1,795,160,090 |
Dividend Yield | 0% |
52-week-range | 5.77 - 18.33 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Website | https://www.iovance.com |
An error occurred while fetching data.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD